[go: up one dir, main page]

AU2003299791A1 - Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity - Google Patents

Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity

Info

Publication number
AU2003299791A1
AU2003299791A1 AU2003299791A AU2003299791A AU2003299791A1 AU 2003299791 A1 AU2003299791 A1 AU 2003299791A1 AU 2003299791 A AU2003299791 A AU 2003299791A AU 2003299791 A AU2003299791 A AU 2003299791A AU 2003299791 A1 AU2003299791 A1 AU 2003299791A1
Authority
AU
Australia
Prior art keywords
imidazol
obesity
dihydro
ones
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299791A
Inventor
Jianqing Chen
Yuanwei Chen
David Gunn
Laszlo Matyas Hunyadi
Reina Natero
Jason Newcom
Stephen James O'Connor
Lin Yi
Hai-Jun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of AU2003299791A1 publication Critical patent/AU2003299791A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003299791A 2002-12-20 2003-12-19 Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity Abandoned AU2003299791A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43542902P 2002-12-20 2002-12-20
US60/435,429 2002-12-20
PCT/US2003/040843 WO2004058727A1 (en) 2002-12-20 2003-12-19 Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity

Publications (1)

Publication Number Publication Date
AU2003299791A1 true AU2003299791A1 (en) 2004-07-22

Family

ID=32682241

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299791A Abandoned AU2003299791A1 (en) 2002-12-20 2003-12-19 Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity

Country Status (2)

Country Link
AU (1) AU2003299791A1 (en)
WO (1) WO2004058727A1 (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105544B2 (en) 2001-07-05 2006-09-12 Synaptic Pharmaceutical Corporation Substituted alkyl amido piperidines
CN102558155A (en) 2003-01-14 2012-07-11 阿伦纳药品公司 Aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of diseases related thereto, such as diabetes and hyperglycemia
US20070032536A1 (en) * 2003-05-15 2007-02-08 Xianping Qian Compounds, compositions and methods
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2005092858A2 (en) 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008503459A (en) 2004-06-16 2008-02-07 ワイス Amino-5,5-diphenylimidazolone derivatives for inhibiting β-secretase
EP1758580A4 (en) 2004-06-24 2008-01-16 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
MX2007003325A (en) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors.
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CN101084212A (en) 2004-09-20 2007-12-05 泽农医药公司 Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AU2005286793A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
CN101083993A (en) 2004-09-20 2007-12-05 泽农医药公司 Heterocyclic derivatives and their use as therapeutic agents
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
EP2264036A1 (en) 2005-01-14 2010-12-22 Wyeth LLC (Formerly Known As Wyeth) Amino-imidazolones for the inhibition of beta-secretase
AU2006211159A1 (en) 2005-02-01 2006-08-10 Wyeth Amino-pyridines as inhibitors of beta-secretase
DE102005025801A1 (en) * 2005-06-02 2006-12-07 Merck Patent Gmbh Use of chromone derivatives
BRPI0611187A2 (en) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc amino thiazide derivatives as inhibitors of human stearoyl coa desaturase
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
BRPI0616757A2 (en) * 2005-09-26 2011-06-28 Wyeth Corp compound of formula i; process for treating a disease or disorder associated with excessive bace activity; process for modulating bace activity; process for treating alzheimer's disease; and pharmaceutical composition
AU2006322060A1 (en) * 2005-12-05 2007-06-14 Incyte Corporation Lactam compounds and methods of using the same
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
GB2435828A (en) * 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted phenyl-piperazine compounds for treatment of food related disorders
GB2435829A (en) * 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Pyrimidinyl-2-piperazine compounds for use in disorders related to food intake
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7700606B2 (en) 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
CN101668751A (en) 2006-12-12 2010-03-10 先灵公司 aspartyl protease inhibitors
JP5271917B2 (en) 2007-01-12 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Spirochromanone derivatives
PE20081559A1 (en) 2007-01-12 2008-11-20 Merck & Co Inc SPIROCHROMANONE DERIVATIVES SUBSTITUTED AS ACETYL COA CARBOXYLASE INHIBITORS
PE20090617A1 (en) 2007-03-23 2009-05-08 Wyeth Corp AMINO-5 - [- 4- (DIFLUOROMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF -SECRETASE
CL2008001839A1 (en) 2007-06-21 2009-01-16 Incyte Holdings Corp Compounds derived from 2,7-diazaspirocycles, inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1; pharmaceutical composition comprising said compounds; Useful to treat obesity, diabetes, glucose intolerance, type II diabetes, among other diseases.
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
US7786155B2 (en) 2007-10-16 2010-08-31 Novartis Ag Organic compounds
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2443016T3 (en) 2009-08-26 2014-02-17 Sanofi New crystalline hydrates of heteroaromatic fluoroglycosides, pharmaceutical products comprising these compounds, and their use
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EA201390421A1 (en) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. GPR119 RECEPTOR MODULATORS AND TREATMENT OF RELATED DISORDERS
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2892892B1 (en) * 2012-09-07 2017-05-31 Janssen Pharmaceutica NV Imidazolin-5-one derivatives useful as fatty acid synthase (fasn) inhibitors for the treatment of cancer
EP3045448A4 (en) 2013-09-12 2017-01-25 Sumitomo Chemical Company Limited Nitrogen-containing saturated heterocyclic compound
CA2934257C (en) * 2013-12-17 2022-06-07 Janssen Pharmaceutica Nv Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer
CN104177298B (en) * 2014-09-18 2018-10-02 湘潭大学 Bis- substitution -4,5- dihydros -1H of 4,4--imidazoles -5- ketone, derivative and its synthetic method
TWI698436B (en) 2014-12-30 2020-07-11 美商佛瑪治療公司 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
HK1248220A1 (en) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
JP2018504431A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Thienopyrimidinone as a ubiquitin-specific protease 7 inhibitor
HK1248221A1 (en) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
PL3310760T3 (en) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
WO2017049321A1 (en) 2015-09-17 2017-03-23 Miller Marvin J Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
CN105272919B (en) * 2015-11-12 2018-01-05 中国科学院过程工程研究所 A kind of method that allantoin is prepared in the oligosaccharide syrup from saline cistanche
CN110520124A (en) 2017-02-16 2019-11-29 艾尼纳制药公司 For treating the Compounds and methods for of primary biliary cholangitis
WO2019170543A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN118146138B (en) * 2024-02-05 2024-11-05 广州安岩仁医药科技有限公司 Preparation method and application of 2-isopropoxy-5-methyl-4-(piperidin-4-yl)aniline hydrochloride

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022108A1 (en) * 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
ES2170446T3 (en) * 1997-12-05 2002-08-01 Hoffmann La Roche DERIVATIVES OF 1,3,8-TRIAZA-ESPIRO (4,5) DECAN-4-ONA.
HN2002000266A (en) * 2001-09-24 2003-11-16 Bayer Corp PREPARATION AND USE OF IMIDAZOL DERIVATIVES FOR THE TREATMENT OF OBESITY.
DE60208815T2 (en) * 2001-10-12 2006-07-20 Bayer Pharmaceuticals Corp., West Haven PHENYL SUBSTITUTES 5-LOW NITROGEN-CONTAINING HETEROCYCLES FOR THE TREATMENT OF FAT ADJUSTMENT

Also Published As

Publication number Publication date
WO2004058727A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
EP2295053B8 (en) Novel 2H-chromen-2-one-3-carboxamides for medical uses
AU2935200A (en) Compounds for the treatment of obesity
PL366619A1 (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
AU2003295890A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003265589A1 (en) Process for the preparation of 1,1,1,2,2-pentafluoroethane
AU2003288023A1 (en) Process for the manufacture of 1,2-epoxy-3-chloropropane
AU2003299648A1 (en) Substituted 4-phenyl-(1,3)-dioxanes
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
AU2003224002A1 (en) Drugs for the arthritis treatment
AU2002236781A1 (en) Treatment for snoring
AU2003233820A1 (en) Method for the treatment of starch
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
AU2003269949A1 (en) Substituted 1,4-pyrazine derivatives
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003237460A1 (en) Combination treatments for purinoceptor-related disorders
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003269482A1 (en) Process for the manufacture of 2,1,3-benzoxadiazole-4-carboxaldehyde
AU2000272704A1 (en) Use of compounds for the treatment of obesity

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase